Background: To improve strategies for the treatment of BRAF-mutant advanced colorectal cancer (aCRC) patients, we examined individual data from patients treated with chemotherapy alone in three randomised trials to identify points on the treatment pathway where outcomes differ from BRAF wild-types.
Introduction
The V600E activating mutation in BRAF (BRAF-mutant) is found in the tumours of 8-12% patients with advanced colorectal cancer (aCRC). BRAF-mutant aCRC is consistently associated with poor overall survival (OS) and progression-free survival (PFS) in case series [1] and randomised controlled trials (RCTs) [2] . In a recent RCT of previously untreated aCRC, median OS was 13.4 months in BRAF-mutant patients compared with 37.1 months in RAS and BRAF wild-types [3] .
The mechanism for the poor prognosis is poorly understood, and it is unclear at what point in the aCRC treatment pathway that BRAF-mutant outcomes diverge from wild-types; whilst OS is uniformly poor, less impact is seen with PFS compared with wild-types [4, 5] . It has been hypothesised that poor outcomes are secondary to intrinsic chemoresistance but there is a paucity of data describing the outcomes of BRAF-mutant aCRC with chemotherapy alone, particularly beyond the first-line. This is particularly important as BRAF-mutant patients have questionable benefit from anti-epidermal growth factor receptor (anti-EGFR) therapies [6] and BRAF-targeted strategies have yet to make clinical impact in aCRC [7, 8] .
Importantly previous publications have not performed careful multivariate analysis. This is critical as BRAF-mutant aCRC is associated with clinicopathological features which are themselves negative prognostic factors [9] , including defective mismatch repair (dMMR) status [4, 10] , right sided primary tumour location (PTL) [11] and a high incidence of peritoneal metastases [12] . The observed poor outcomes may instead be driven by such factors so it is essential to prospectively factor these into analyses of outcomes.
This paper provides detailed analysis of the natural history of BRAF-mutant aCRC to give more clarity about prognosis and an evidence base to quantitate the benefits of different chemotherapy strategies throughout the treatment pathway.
In a pre-planned analysis, we have examined individual patient data from three RCTs to identify points on the treatment pathway at which BRAF-mutant outcomes differ from BRAF wild-type patients treated with cytotoxic chemotherapy, to assess the impact of potential confounders and to provide clinicians with detailed information of outcomes with various chemotherapy strategies. We analysed treatment outcomes in two first-line RCTs with oxaliplatin/fluorouracil (OxFU), behaviour during chemotherapyfree intervals and following disease progression. We then report patterns of, and outcomes with second-line therapy. In order to avoid potential interactions of BRAF status with anti-EGFR drugs, we focus on patients treated in arms that did not include targeted therapies. Potential confounding factors were prospectively identified, and analyses adjusted accordingly. BRAF-status was unknown to clinicians treating patients in each trial, eliminating potential bias. Figure 1 , available at Annals of Oncology online).
Patients and methods

Patient population and treatment
Inclusion criteria for FOCUS and COIN were consistent. National ethical approval and patient consent was obtained for all aspects of the clinical and translational research. DNA extraction and genotyping for mutations including BRAF V600E was performed retrospectively as previously reported [16, 18, 19] .
Statistical analysis
Stata was used (Release 12 (2011), StataCorp). Baseline patient characteristics were compared between BRAF-mutant patients (with or without other MEK/AKT pathway mutations) and BRAF wild-type patients using two-tailed T-tests, Wilcoxon rank sum tests and Pearson Chi-squared tests.
Endpoints used were OS (time from randomisation to death from any cause), PFS (time from randomisation to first evidence of progression or death); 12-week RECIST response rate (RR) and disease control rate (DCR) [20] . Finally, we compared post-progression survival (P-PS) time, defined as time from progression to death in those with a progression event; however, when date of progression data was unavailable, date of last chemotherapy cycle was used instead.
The prognostic influence of BRAF-mutant status on survival outcomes were analysed using Cox proportional hazards modelling and described using hazard ratios (HRs) and 95% confidence intervals (CIs), adjusted for factors known to be prognostic or likely to interact with BRAF-status. In COIN and FOCUS: WHO performance status (2 versus 0/1); primary tumour resected (yes versus no); PTL (right colon versus other); platelet count (< versus 400 000/ll); peritoneal metastases (present versus absent) and mismatch repair (MMR) status. In PICCOLO, adjustment was made for: response to previous therapy; performance status; peritoneal metastases; primary tumour resected and PTL. As these factors individually interact with prognosis, adjusted values are reported primarily but unadjusted values are provided.
Kaplan-Meier (KM) curves were plotted. For response endpoints, odds ratios (ORs) and 95% CIs were estimated from logistic regression models for the effect of BRAF-mutant status, adjusted for the markers previously described. Table 2 , available at Annals of Oncology online). We examined the impact of chemotherapy-free intervals on PFS in BRAF-mutant patients in COIN. In all patients progression events in patients during chemotherapy breaks led to shorter PFS (adjusted HR ¼ 1.27 [1.21-1.33], P < 0.001) [19] . BRAF-mutant patients were the only molecular sub-group not to have a PFS dis- Table 2 , available at Annals of Oncology online).
Results
Clinicopathological variables associated with
Outcomes of BRAF-mutant patients treated with anti-EGFR agents in COIN and PICCOLO have been previously reported [9, 18] , and are discussed in the supplementary Material (available at Annals of Oncology online).
Impact of BRAF-status on P-PS
Following progression on first-line combination chemotherapy, BRAF-mutant patients had markedly reduced P-PS compared with wild-types in both first-line trials. In COIN, PPS was 3.2 months in BRAF-mutant compared with 8. Table 2 , available at Annals of Oncology online).
When other prognostic factors were tested in a combined multivariate model, a significant negative effect on P-PS was seen after first-line chemotherapy for peritoneal metastases and dMMR status (peritoneal metastases HR ¼ 1.39, P < 0.0001; dMMR HR ¼ 1.38, P ¼ 0.025). However, the negative prognostic impact of peritoneal metastases and dMMR appears limited to the BRAF wild-type population, and neither factor impacted further on the poor P-PS seen in BRAF-mutant patients (interaction P¼ 0.005 and P ¼ 0.05, respectively), suggesting that it is the BRAF-mutation driving the observed poor outcomes (supplementary Table 3 , available at Annals of Oncology online).
To explore the mechanism for inferior first-line P-PS in BRAFmutant patients, we studied uptake of post-progression therapies. In COIN, BRAF-mutant patients were less likely to receive second-line therapy after first-line progression (33% versus. 51%, P ¼ 0.0002). Similarly, after completion of the FOCUS plan, which for all patients included two drugs (FU and either oxaliplatin or irinotecan, given over 1 or 2 lines), 123/401 (30.7%) BRAF wild-type and 3/29 (10.3%) BRAF-mutant patients received subsequent salvage therapy (P ¼ 0.020).
We then performed an exploratory analysis to ascertain whether the reduction in P-PS in BRAF-mutant patients was due to rapid progression after initial first-line benefit, rapid progression in patients who also rapidly progressed through first-line treatment, or both. Table 3 shows the breakdown of patients by mutational status into four groups depending on the duration of first-line PFS and subsequent P-PS: good PFS/P-PS defined as greater than 6 months, poor PFS/P-PS defined as less than 6 months. Table 3 . Breakdown of all patients by PFS and P-PS duration, then proportion of patients in each PFS/P-PS grouping by mutation status *Good PFS or P-PS is >6 months; poor PFS or P-PS is <6 months. **Nine patients had BRAF and RAS mut.
Fewer BRAF-mut patients had good first-line PFS and good P-PS compared with wild-type patients (24.3% versus 39.3%, P < 0.001). Conversely, there was a significantly higher proportion of BRAF-mutant patients with very poor outcomes (both less than 6 months first-line PFS and P-PS) compared with wildtype patients (36.5% and 21.9%, respectively, P < 0.001). Thus, around a third of BRAF-mutant patients not only fail to obtain useful benefit from first-line therapy but also rapidly progress thereafter. The median survival of BRAF-mutant patients in these two groups is 24.0 and 4.7 months respectively. There were no significant differences in patient demographics between these two groups; however, there was a trend towards lower median age in the poor PFS/P-PS compared with the good PFS/P-PS group (61.9 versus 65.2, P ¼ 0.07).
Further difference in treatment patterns was observed: 67.5% of BRAF wild-type patients with good initial PFS also had a good P-PS compared with 48.4% of the BRAF-mutant patients (P < 0.001). Whilst 47.4% of BRAF wild-type patients in spite of an initial poor first-line PFS went onto have a greater than 6 months P-PS, this was the case in just 26.6% of BRAF-mutant patients.
Discussion
This is the largest and most comprehensive clinical series assessing the outcomes of BRAF-mutant patients treated with chemotherapy at different points of the aCRC pathway. In a careful multivariate analysis in a large, prospectively gathered cohort, BRAF-mutation still conferred a worse prognosis and is not simply attributable to associated clinicopathological features.
Within this dataset, the poor outlook is not driven by chemoresistance. We observed no difference in the adjusted PFS or DCR between BRAF-mutant and wild-type patients receiving first-line chemotherapy. There was also no difference in adjusted PFS or DCR between BRAF-mutant and wild-type patients who received second-line irinotecan monotherapy. Results were consistent among both first-line trials, independent of chemotherapy strategy and other standard prognostic factors. OxFU is a commonly used first-line therapy in aCRC, and was the first-line regimen used in the majority of patients analysed herein, and indeed oxaliplatin may provide particular benefits in BRAF-mutant patients [3, 21] .
Our analyses suggest instead that the point at which outcomes markedly diverge between BRAF-mutant and wild-types is following progression on or after benefit from first-line chemotherapy. Further investigation suggested that the observed significantly worse P-PS compared with wild-types may be due to the combined impact of two distinct patterns. First, BRAF-mutant patients were more likely to rapidly progress through firstline therapy and then subsequently rapidly deteriorate, either too unfit to receive subsequent treatment or progressing through that therapy. Secondly, BRAF-mutant patients with an initial good outcome on first-line chemotherapy were more likely to rapidly progress thereafter. Whilst around two-thirds of wild-type patients with good outcomes on initial therapy subsequently survive more than 6 months after progression on first-line chemotherapy this fell to half of BRAF-mutant patients.
Although the study is limited by relative small numbers of BRAF-mutant patients compared with wild-types and findings should be interpreted with caution particularly sub-group analyses, the data suggest that a significant proportion of BRAFmutant patients can obtain meaningful benefit from chemotherapy. Thus, uniform nihilism about the impact of chemotherapy in deflecting the natural history of BRAF-mutant aCRC is unjustified. Furthermore, BRAF-mutant patients with disease control can be appropriately counselled about the safety of chemotherapy free intervals, even though caution is required in the interpretation of this sub-set analysis. However, post-progression survival after first-line progression is clearly worse in BRAF-mutant patients and fewer receive second-line therapy. It is important to emphasise that treating physicians were unaware of BRAF-status, so this latter finding is not due to selection bias. Thus, we suggest that extra vigilance is required when treating BRAF-mutant patients, to promptly detect initial progression and then rapidly institute second-line therapy in the knowledge that this has the capacity to significantly improve survival.
A third of BRAF-mutant patients rapidly progress on and then after first-line therapy with no obvious benefit from chemotherapy. These patients drive much of the observed poor outcomes of BRAF-mutant aCRC and such aggressive clinical behaviour is what clinicians often have in mind when thinking about BRAFmutant aCRC patients. A biomarker is required to identify such patients who might benefit from an alternative therapeutic strategy, such as targeted therapy. The combination of a BRAFinhibitor dabrafenib, a MEK inhibitor trametinib and an anti-EGFR agent panitumumab demonstrated an unconfirmed response rate of 30% [22] .
Recent transcriptional analyses have sub-divided BRAF-mutant aCRC into two sub-types with widely differing biology [23] . BM1 tumours constitute one-third of BRAF-mutant cancers and are characterized by enrichment of a KRAS signature and sensitivity to BRAF and MEK inhibition. The other twothirds of BRAF-mutant aCRC, the BM2 sub-type, are characterized by accelerated G2/M phase with low ATM with sensitivity to cdk1 inhibition. These checkpoint abnormalities could contribute to chemosensitivity by preventing DNA damage being repaired prior to mitosis. Thus, application of these signatures to these two clinically divergent groups of BRAF-mutant patients appears warranted. Furthermore MMR testing should be encouraged in BRAF-mutant aCRC patients and entry into RCT testing immunotherapy agents where available.
This, the largest and most comprehensive analysis of chemotherapy outcomes in BRAF-mutant CRC patients provides new and important information with clinical relevance. In summary, BRAF-mutation confers a markedly worse prognosis independent of associated clinicopathological features. However, in some patients, chemotherapy does provide meaningful improvements in outcome throughout treatment lines and translational efforts need to be made to identify them and those who appear to derive no benefit from chemotherapy. P-PS is worse in BRAF-mutant patients and vigilance is required to ensure the appropriate delivery of treatment after first-line progression.
